| 1.1 Symptomatic thromboembolic events |
4 |
476 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.39 [0.08, 1.98] |
| 1.1.1 LMWH |
4 |
476 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.39 [0.08, 1.98] |
| 1.2 Symptomatic pulmonary embolism |
3 |
187 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.02, 7.14] |
| 1.2.1 LMWH |
3 |
187 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.02, 7.14] |
| 1.3 Symptomatic deep vein thrombosis |
4 |
227 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.04, 3.10] |
| 1.3.1 LMWH |
3 |
187 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.01, 7.93] |
| 1.3.2 UFH |
1 |
40 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.01, 7.72] |
| 1.4 Blood transfusion |
1 |
16 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 1.4.1 LMWH |
1 |
16 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 1.5 Bleeding episodes |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 1.5.1 LMWH: placental abruption |
3 |
463 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.31, 3.20] |
| 1.5.2 LMWH: peripartum haemorrhage |
1 |
289 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.65 [0.24, 1.79] |
| 1.5.3 LMWH non‐major/minor bleeding |
1 |
284 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.12 [1.15, 3.93] |
| 1.5.4 LMWH: major bleeding |
1 |
284 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.48 [0.25, 8.72] |
| 1.5.5 UFH: antenatal vaginal bleeding |
1 |
40 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.16, 6.42] |
| 1.5.6 UFH: postpartum haemorrhage |
1 |
40 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.00 [0.13, 69.52] |
| 1.6 Serious wound complications |
1 |
16 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 1.6.1 LMWH |
1 |
16 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 1.7 Adverse effects sufficient to stop treatment |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 1.7.1 LMWH |
1 |
139 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.49 [0.05, 5.31] |
| 1.8 Adverse effects not sufficient to stop treatment |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 1.8.1 LMWH: skin/allergic reactions |
4 |
476 |
Risk Ratio (M‐H, Fixed, 95% CI) |
5.11 [2.00, 13.08] |
| 1.8.2 LMWH: raised liver enzymes |
1 |
289 |
Risk Ratio (M‐H, Fixed, 95% CI) |
22.53 [1.34, 378.78] |
| 1.8.3 LMWH: haematoma |
2 |
171 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.98 [0.46, 34.23] |
| 1.8.4 Superficial thrombophlebitis |
1 |
139 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.01, 7.93] |
| 1.8.5 LMWH: other |
1 |
289 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.06, 15.51] |
| 1.9 Symptomatic osteoporosis |
4 |
479 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.00 [0.13, 69.52] |
| 1.9.1 LMWH |
3 |
439 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 1.9.2 UFH |
1 |
40 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.00 [0.13, 69.52] |
| 1.10 Fetal loss |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 1.10.1 LMWH or UFH: gestation unclear |
2 |
329 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.16 [0.54, 2.51] |
| 1.10.2 LMWH: < 20 weeks |
2 |
171 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.18 [0.50, 9.41] |
| 1.10.3 LMWH: ≥ 20 weeks |
2 |
166 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.04, 3.12] |
| 1.11 Thrombocytopenia |
5 |
511 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.00 [0.14, 64.26] |
| 1.11.1 LMWH |
4 |
471 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.00 [0.14, 64.26] |
| 1.11.2 UFH |
1 |
40 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 1.12 Fetal anomalies |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 1.12.1 LMWH |
1 |
289 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.94 [0.60, 14.32] |
